Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Harmony Biosciences Holdings Inc (HRMY)

Harmony Biosciences Holdings Inc (HRMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,235,877
  • Shares Outstanding, K 57,596
  • Annual Sales, $ 714,730 K
  • Annual Income, $ 145,490 K
  • EBIT $ 226 M
  • EBITDA $ 248 M
  • 60-Month Beta 0.80
  • Price/Sales 3.14
  • Price/Cash Flow 13.21
  • Price/Book 2.68

Options Overview Details

View History
  • Implied Volatility 54.74% (-2.25%)
  • Historical Volatility 28.93%
  • IV Percentile 41%
  • IV Rank 18.11%
  • IV High 127.87% on 09/15/25
  • IV Low 38.57% on 01/21/25
  • Expected Move (DTE 8) 0.38 (0.97%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 66
  • Volume Avg (30-Day) 220
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 5,474
  • Open Int (30-Day) 6,458
  • Expected Range 38.89 to 39.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.79
  • Number of Estimates 5
  • High Estimate 1.21
  • Low Estimate 0.60
  • Prior Year 0.85
  • Growth Rate Est. (year over year) -7.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.64 +24.12%
on 11/11/25
40.00 -1.82%
on 12/08/25
+7.45 (+23.41%)
since 11/10/25
3-Month
25.52 +53.88%
on 10/20/25
40.00 -1.82%
on 12/08/25
+6.06 (+18.25%)
since 09/10/25
52-Week
25.52 +53.88%
on 10/20/25
40.93 -4.06%
on 01/21/25
+6.56 (+20.06%)
since 12/10/24

Most Recent Stories

More News
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome

Data presented at the 2025 American Epilepsy Society Annual Meeting

HRMY : 39.27 (+1.16%)
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will highlight new open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing...

HRMY : 39.27 (+1.16%)
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

New Drug Application to be submitted in early 2026; target PDUFA in Q1 2027 Utility patent applications filed with potential exclusivity to 2044

HRMY : 39.27 (+1.16%)
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence

BP1.15205 is a differentiated chemical scaffold, demonstrating high potency and selectivity in preclinical studies with a favorable safety profile and the potential for once-daily dosing ...

HRMY : 39.27 (+1.16%)
Harmony Biosciences to Participate in Upcoming Investor Conferences

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Citi's 2025 Global Healthcare...

HRMY : 39.27 (+1.16%)
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

WAKIX® (pitolisant) Franchise Delivers Net Revenue of $239M in Q3 2025 (+29% YoY Growth) Record Increase in Average Number of Patients of Approximately 500 to Achieve...

HRMY : 39.27 (+1.16%)
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following: WAKIX® (pitolisant) franchise delivered net revenue...

HRMY : 39.27 (+1.16%)
UBS Reaffirms Their Buy Rating on Harmony Biosciences Holdings (HRMY)

UBS analyst Ashwani Verma maintained a Buy rating on Harmony Biosciences Holdings today and set a price target of $43.00. The company’s shares closed yesterday at $26.36.Elevate Your Investing Strategy:...

HRMY : 39.27 (+1.16%)
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). The RECONNECT...

HRMY : 39.27 (+1.16%)
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36 th International Epilepsy Congress (IEC) being held...

HRMY : 39.27 (+1.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Harmony Biosciences Holdings Inc.is a pharmaceutical company. It engages in developing and commercializing therapies for rare neurological disorders. Harmony Biosciences Holdings Inc.is based in Plymouth Meeting, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 41.26
2nd Resistance Point 40.40
1st Resistance Point 39.83
Last Price 39.27
1st Support Level 38.41
2nd Support Level 37.55
3rd Support Level 36.99

See More

52-Week High 40.93
Last Price 39.27
Fibonacci 61.8% 35.04
Fibonacci 50% 33.22
Fibonacci 38.2% 31.41
52-Week Low 25.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar